We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Seeks More Data on Forest and Gedeon Richter’s Schizophrenia Drug
FDA Seeks More Data on Forest and Gedeon Richter’s Schizophrenia Drug
The FDA has handed Forest Laboratories and Gedeon Richter a complete response letter asking for more data on cariprazine, the companies’ drug candidate to treat schizophrenia and manic or mixed episodes of bipolar I disorder in adults.